The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent

Cancer Biology and Therapy

Volumn 16, Issue 1, 2015, Pages 34-42

  Li, Chen ^a   Cui, Jian Feng ^b   Chen, Min Bin ^c   Liu, Chao Ying ^d   Liu, Feng ^a   Zhang, Qian De ^e   Zou, Jian ^d   Lu, Pei Hua ^d,f  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b CHENGDU MILITARY GENERAL HOSPITAL   (China)

^c KUNSHAN FIRST PEOPLE S HOSPITAL AFFILIATED TO JIANGSU UNIVERSITY   (China)

^d WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

^e THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^f NANJING MEDICAL UNIVERSITY   (China)

Author keywords

cell growth and migration; colorectal cancer; INK 128; mTOR

Indexed keywords

BINIMETINIB; FASCIN; FASCIN 1; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MITOGEN ACTIVATED PROTEIN KINASE; SAPANISERTIB; UNCLASSIFIED DRUG; UVOMORULIN; ACTIN BINDING PROTEIN; ANTINEOPLASTIC AGENT; BENZOXAZOLE DERIVATIVE; CADHERIN; CARRIER PROTEIN; FSCN1 PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL MIGRATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG SCREENING; ENZYME ACTIVATION; ENZYME INHIBITION; HT-29 CELL LINE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MTOR SIGNALING; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; COLORECTAL NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; HT 29 CELL LINE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOXAZOLES; CADHERINS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLUOROURACIL; HT29 CELLS; HUMANS; MALE; MICE; MICROFILAMENT PROTEINS; MULTIPROTEIN COMPLEXES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84936890657     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/15384047.2014.972274     Document Type: Article

References (33)

1. Schmoll HJ, Stein A. Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection. Nat Rev Clin Oncol 2014; 11:79-80. PMID:24445520.
2. Kuipers EJ, Rosch T, Bretthauer M. Colorectal cancer screening–optimizing current strategies and new directions. Nat Rev Clin Oncol 2013; 10:130-42. PMID:23381005.
3. Brouquet A, Nordlinger B. Metastatic colorectal cancer outcome and fatty liver disease. Nat Rev Gastroenterol Hepatol 2013; 10:266-7. PMID:23567218.
4. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29. PMID:24399786.
5. Ekstrand AI, Jonsson M, Lindblom A, Borg A, Nilbert M. Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Fam Cancer 2010; 9:125-9. PMID:19731079.
6. Zhang YJ, Dai Q, Sun DF, Xiong H, Tian XQ, Gao FH, et al. mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann Surg Oncol 2009; 16:2617-28. PMID:19517193.
7. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9-22. PMID:17613433.
8. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6:729-34. PMID:16915295.
9. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274-93. PMID:22500797.
10. Sun SY. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett 2013; 340:1-8. PMID:23792225.
11. Garcia-Garcia C, Ibrahim YH, Serra V, Calvo MT, Guzman M, Grueso J, et al. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res 2012; 18:2603-12. PMID:22407832.
12. Garcia-Echeverria C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg Med Chem Lett 2010; 20:4308-12. PMID:20561789.
13. Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, Van Waes C. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets 2011; 15:63-74. PMID:21110697.
14. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118:3065-74. PMID:18725988.
15. Ma Y, Machesky LM. Fascin1 in carcinomas: Its regulation and prognostic value. Int J Cancer 2014. PMID:25302416.
16. Chen MB, Wei MX, Han JY, Wu XY, Li C, Wang J, et al. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer. Cell Signal 2014; 26:102-9. PMID:23899558.
17. Hu M, Xia M, Chen X, Lin Z, Xu Y, Ma Y, et al. MicroRNA-141 regulates Smad interacting protein 1 (SIP1) and inhibits migration and invasion of colorectal cancer cells. Dig Dis Sci 2010; 55:2365-72. PMID:19830559.
18. Fabre M, Garcia de Herreros A. Phorbol ester-induced scattering of HT-29 human intestinal cancer cells is associated with down-modulation of E-cadherin. J Cell Sci 1993; 106 (Pt 2):513-21. PMID:8282758.
19. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000; 275:36803-10. PMID:10969078.
20. Chung KY, Saltz LB. Adjuvant therapy of colon cancer: current status and future directions. Cancer J 2007; 13:192-7. PMID:17620769.
21. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006; 25:6436-46. PMID:17041628.
22. Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 2011; 10:395-403. PMID:21216931.
23. Van Duyne GD, Standaert RF, Karplus PA, Schreiber SL, Clardy J. Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. J Mol Biol 1993; 229:105-24. PMID:7678431.
24. O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-8. PMID:16452206.
25. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011; 2:135-64. PMID:21411864.
26. Li Q, Song XM, Ji YY, Jiang H, Xu LG. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro. Biochem Biophys Res Commun 2013; 440:701-6. PMID:24103749.
27. Rhoads JM, Niu X, Odle J, Graves LM. Role of mTOR signaling in intestinal cell migration. Am J Physiol Gastrointest Liver Physiol 2006; 291:G510-7. PMID:16710051.
28. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98:2277-83. PMID:8941644.
29. Liu Y, Cao GF, Xue J, Wan J, Wan Y, Jiang Q, et al. Tumor necrosis factor-alpha (TNF-alpha)-mediated in vitro human retinal pigment epithelial (RPE) cell migration mainly requires Akt/mTOR complex 1 (mTORC1), but not mTOR complex 2 (mTORC2) signaling. Eur J Cell Biol 2012; 91:728-37. PMID:22595285.
30. Berven LA, Willard FS, Crouch MF. Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration. Exp Cell Res 2004; 296:183-95. PMID:15149849.
31. Bu X, Le C, Jia F, Guo X, Zhang L, Zhang B, et al. Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells. Cancer Biol Ther 2008; 7:392-6. PMID:18075305.
32. Lee KH, Hur HS, Im SA, Lee J, Kim HP, Yoon YK, et al. RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. Cancer Lett 2010; 299:22-8. PMID:20727673.
33. Punt CJ, Boni J, Bruntsch U, Peters M, Thielert C. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 2003; 14:931-7. PMID:12796032.